| Released | Contributor | Author | Title | Pages | Price |
| 27-Nov-2009 | Pechala's Reports | Lubomir Pechala | ARYS THERAPEUTICS INC (ARYX=US) 2-weeks forecast | 1 |
$10 |
| 27-Nov-2009 | Pechala's Reports | Frantisek Pechala | ARYS THERAPEUTICS INC (ARYX=US) 12-months forecast | 1 |
$15 |
| 26-Nov-2009 | ValuEngine, Inc. |
N/A
| ValuEngine Industry Report for BIOTECHNOLOGY | 18 |
$49 |
| 25-Nov-2009 | Zacks Investment Research Inc. |
N/A
| ARYX THERAPEUT (ARYX) Zacks Company Snapshot | 1 |
$10 |
| 23-Nov-2009 | PriceTarget Research, Inc. |
N/A
| Drug Intelligence Monitor: overall outlook NEUTRAL - 25 new Leaders; 25 new Laggards. | 65 |
$20 |
| 23-Nov-2009 | ValuEngine, Inc. |
N/A
| ValuEngine Detailed Valuation Report for ARYX | 13 |
$25 |
| 21-Nov-2009 | Standard & Poor's Quantitative Report |
N/A
| ARYx Therapeutics | 5 |
$25 |
| 19-Nov-2009 | Ford Investor Services, Inc. |
N/A
| Industry Value Graph: ARYX , DSCO , HEPH , ICGN , MSHL , OGXI , PIP , SOMX -- DRUGS | 3 |
$4 |
| 19-Nov-2009 | Ford Investor Services, Inc. |
N/A
| Value Graph: ARYX THERAPEUTIC -- ARYX | 1 |
$4 |
| 12-Nov-2009 | Jefferson Research |
N/A
| Jefferson Research Financial Sonar Report. A detailed analysis of the current fundamental performance of ARYX THERAPEUTICS INC including Earnings Quality, Cash Flow Quality, Operating Efficiency, Balance Sheet Quality and Valuation. | 3 |
$20 |
1.48% Nasdaq 
Research Reports
